AR091836A1 - Metodo para purificar el factor transgenico vii - Google Patents

Metodo para purificar el factor transgenico vii

Info

Publication number
AR091836A1
AR091836A1 ARP130102563A ARP130102563A AR091836A1 AR 091836 A1 AR091836 A1 AR 091836A1 AR P130102563 A ARP130102563 A AR P130102563A AR P130102563 A ARP130102563 A AR P130102563A AR 091836 A1 AR091836 A1 AR 091836A1
Authority
AR
Argentina
Prior art keywords
tgfviia
tgfvii
factor vii
ligand
transgenic
Prior art date
Application number
ARP130102563A
Other languages
English (en)
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of AR091836A1 publication Critical patent/AR091836A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente se refiere a un ligando de afinidad anti-Factor VII que es particularmente útil para purificar el factor VII activado humano recombinante de fuentes transgénicas. El ligando de afinidad combinado con otras etapas cromatográficas ortogonales permite la preparación de una solución de FVII muy purificada libre de agregados con un bajo porcentaje de formas de FVII degradadas u oxidadas. Reivindicación 1: Un método para purificar el Factor VII transgénico (TgFVII) y/o Factor VII activado transgénico (TgFVIIa) a partir de un material de fuente biológica, que comprende una etapa de cromatografía por afinidad que comprende las etapas de: (a) poner en contacto un material de fuente biológica que contiene TgFVII y/o TgFVIIa con un ligando que es específico de TgFVII y/o TgFVIIa, en condiciones que permiten que el TgFVII y/o TgFVIIa se una con el ligando y (b) recuperar TgFVII y/o TgFVIIa por disrupción de una manera no destructiva de la interacción con dicho ligando.
ARP130102563A 2012-07-19 2013-07-18 Metodo para purificar el factor transgenico vii AR091836A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12305882.8A EP2687595B1 (en) 2012-07-19 2012-07-19 Method for purifying transgenic factor VII

Publications (1)

Publication Number Publication Date
AR091836A1 true AR091836A1 (es) 2015-03-04

Family

ID=48856605

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102563A AR091836A1 (es) 2012-07-19 2013-07-18 Metodo para purificar el factor transgenico vii

Country Status (19)

Country Link
US (1) US9982247B2 (es)
EP (2) EP2687595B1 (es)
JP (1) JP6219947B2 (es)
KR (2) KR20140129015A (es)
CN (1) CN104640980B (es)
AR (1) AR091836A1 (es)
AU (1) AU2013291969B2 (es)
CA (1) CA2879109C (es)
DK (1) DK2875129T3 (es)
ES (1) ES2703541T3 (es)
IL (1) IL236755B (es)
MX (1) MX358139B (es)
MY (1) MY172995A (es)
PH (1) PH12015500083A1 (es)
PL (1) PL2875129T3 (es)
SG (1) SG11201500254PA (es)
TR (1) TR201818506T4 (es)
TW (1) TWI531576B (es)
WO (1) WO2014013024A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1711513B1 (en) 2003-12-01 2014-07-02 Novo Nordisk Health Care AG Nanofiltration of factor vii solutions to remove virus
CN103429272A (zh) 2010-12-30 2013-12-04 法国化学与生物科技实验室 作为病原体灭活剂的二元醇
FR3006591B1 (fr) 2013-06-11 2016-05-06 Lab Francais Du Fractionnement Composition de facteur vii presentant un point isoelectrique substantiellement homogene
FR3082427B1 (fr) * 2018-06-14 2020-09-25 Lab Francais Du Fractionnement Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
CN114438061B (zh) * 2020-10-30 2023-10-20 北京双鹭立生医药科技有限公司 用于纯化凝血因子vii的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
FR2632524B1 (fr) 1988-06-09 1992-03-13 Fondation Nale Transfusion San Procede de preparation d'une fraction concentree en facteur viia et son application a titre de medicament
FR2677652B1 (fr) 1991-06-12 2005-05-27 Agronomique Inst Nat Rech Procede de preparation d'une proteine d'interet dans le lait d'un animal transgenique, produit obtenu et cellule eucaryote utilisee.
FR2684999A1 (fr) 1991-12-16 1993-06-18 Aquitaine Dev Transf Sanguine Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag.
DE69334258D1 (de) 1992-08-21 2009-02-26 Univ Bruxelles Immunoglobuline ohne Leichtkette
DK38293D0 (da) 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
ES2162863T3 (es) * 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
TWI268933B (en) 2003-06-10 2006-12-21 Animal Technology Inst Taiwan Method for separating protein from animal milk
FR2901796A1 (fr) 2006-05-31 2007-12-07 Lab Francais Du Fractionnement Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
FR2910786B1 (fr) 2006-12-29 2017-08-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) "procede d'extraction d'une proteine presente dans du lait"
JP2011517562A (ja) 2008-03-25 2011-06-16 バイオプロテイン テクノロジーズ エスエー ヒト第ｖｉｉ因子を産生するトランスジェニックウサギ
JP2011520999A (ja) 2008-05-23 2011-07-21 ノボ ノルディスク ヘルス ケア アーゲー 高濃度の芳香族保存料を有するペグ官能化セリンプロテアーゼの製剤
FR2942233B1 (fr) * 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
FR2947181B1 (fr) 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
CN102161701A (zh) * 2011-01-28 2011-08-24 上海兴迪金生物技术有限公司 从细胞培养液或血浆组分中分离纯化高纯度活化凝血七因子的方法

Also Published As

Publication number Publication date
US9982247B2 (en) 2018-05-29
KR20170083166A (ko) 2017-07-17
SG11201500254PA (en) 2015-02-27
TR201818506T4 (tr) 2019-01-21
ES2703541T3 (es) 2019-03-11
TW201416373A (zh) 2014-05-01
EP2875129B1 (en) 2018-09-05
US20150175983A1 (en) 2015-06-25
CN104640980B (zh) 2019-01-08
MX358139B (es) 2018-08-06
AU2013291969A1 (en) 2015-02-05
PH12015500083A1 (en) 2015-03-02
MX2015000778A (es) 2015-10-14
AU2013291969B2 (en) 2018-07-12
IL236755B (en) 2018-03-29
CA2879109A1 (en) 2014-01-23
KR20140129015A (ko) 2014-11-06
CA2879109C (en) 2019-03-05
MY172995A (en) 2019-12-18
EP2687595B1 (en) 2018-05-30
PL2875129T4 (pl) 2019-03-29
EP2875129A1 (en) 2015-05-27
KR101842412B1 (ko) 2018-03-26
TWI531576B (zh) 2016-05-01
JP2015522600A (ja) 2015-08-06
DK2875129T3 (en) 2019-01-07
EP2687595A1 (en) 2014-01-22
WO2014013024A1 (en) 2014-01-23
PL2875129T3 (pl) 2019-03-29
CN104640980A (zh) 2015-05-20
JP6219947B2 (ja) 2017-10-25

Similar Documents

Publication Publication Date Title
AR091836A1 (es) Metodo para purificar el factor transgenico vii
EA201391564A1 (ru) Полипептиды антитела, которые антагонизируют cd40
CY1123079T1 (el) Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων
CO2018004090A2 (es) Anticuerpos anti-tigit y métodos de uso
EA201592302A1 (ru) Способы снижения уровня остаточного холестерина и других фракций липопротеинов путем введения ингибитора пропротеиновой конвертазы субтилизин-кексинового типа 9 (pcsk9)
CR20110606A (es) Uso de un anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales
CR20110296A (es) Anticuerpos humanos de alta afinidad contra pcsk9
BR112014012275A2 (pt) purificação de proteína com a utilização de tampão bis-tris
UY34975A (es) ANTICUERPOS ANTI-PCSK9 CON CARACTERÍSTICAS DE UNIÓN DEPENDIENTES DEL pH
CR20120086A (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana
CO7151488A2 (es) Anticuerpos de reacción cruzada anti-jagged1/jagged 2, anticuerpos anti-jagged activables y métodos de uso de los mismos
MA38308B1 (fr) Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t
CO6741179A2 (es) Mutantes fc de anticuerpos resistentes a proteasas activas
CL2017002233A1 (es) Un factor de coagulación (fvii o fviia) modificado con tres péptidos carboxi terminal de gonadotropina coriónica unidos al carboxi terminal de fvii o fviia; polinucleótido que lo codifica; composición farmacéutica que lo comprende; uso de fvii o fviia modificado para el tratamiento de coagulación de la sangre o un trastorno de coagulación; método para extender la vía media biológica de un factor de coagulación; método para producir dicho fvii o fviia.
BR112015027812A2 (pt) processo contínuo de multietapa para purificação de anticorpos
CR9576A (es) METODOS PARA PURIFICAR PROTEINAS QUE CONTIENE LA REGION Fc
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
AR062570A1 (es) Proceso para la purificacion de las proteinas que contienen fc
ES2674177T3 (es) Preparación de suero
TR201911082T4 (tr) K vitaminine bağımlı proteinlerin saflaştırılması için bir işlem.
BR112015000188A2 (pt) isolados de proteína de batata
BR112014032916A2 (pt) anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
BR112013013904A2 (pt) dispositivo de comutação de um mecanismo de troca de marchas de um automóvel, bucha de um dispositivo de comutação e método para a fabricação de uma bucha
PE20141826A1 (es) Uso de composiciones nutricionales que incluyen lactoferrina en apoyo a la resistencia a enfermedades y condiciones
BR112013030008A2 (pt) imunoensaio de clozapina

Legal Events

Date Code Title Description
FB Suspension of granting procedure